Abstract
The influence of human pancreatic growth hormone-releasing factor (hpGRF-44) on GH secretion was investigated in 15 patients with active acromegaly. Following the administration of hpGRF-44 (1 μg/kg, iv) mean (+ SE) serum GH level increased from 22.4 ± 6.3 ng/ml to 42.9 ± 8.2. ng/ml (peak, p < 0.01). The pattern and the magnitude of the GH rises were widely variable and it was possible to identify three types of responses: in fact in 2 cases a very large serum GH rise, eight folds over baseline, was observed, in 7 patients a clear GH stimulation, two-three fold over baseline was noticed and in 6 patients no significant GH modifications were seen. No correlation was found between the response to hpGRF-44 and the existence of abnormal GH responses to dopamine infusion, TRH and dopamine-sulpiride test. In 5 acromegalic patients hpGRF-44 was injected again after transsphenoidal adenomectomy. The magnitude of serum GH response decreased in one hyperresponsive patient, increased in 2 previously unresponsive cases and did not change in the remaining cases. In 6 GH responsive patients hpGRF-44 was injected at 120 min during a 4 hour infusion of somatostatin (GHRIH, 3.33 μg/min). GHRIH infusion significantly suppressed GH levels in all the patients and blunted the hpGRF-44 stimulated GH increase. The different patterns of GH response to hpGRF-44 in acromegalic patients suggest a different sensitivity of the adenomatous somatotrophs and a possible contribution by normal GH-secreting cells to hpGRF-44 induced GH response.
Similar content being viewed by others
References
Guillemin R., Brazeau P., Bohlen P., Esch F., Ling N., Weherenberg W.B. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 218: 585, 1982.
Rivier J., Spiess J., Thorner M., Vale M. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumor. Nature 300: 276, 1982.
Borges J.L.C., Blizzard R.M., Gelato M.C., Furianetto R., Rogol A.D., Evans W.S., Vance M.L., Kaiser D.L., Mac Leod R.M., Merriam G.R., Loriaux D.L., Spiess J., Rivier J., Vale W., Thorner M.O. Effects of human pancreatic tumor growth hormone releasing factor on growth hormone and somatomedin C levels in patients with idiopathic growth hormone deficiency. Lancet 2: 119, 1983.
Gelato M.C., Pescovitz O., Cassorla F., Loriaux D.L., Merriam G.R. Effects of a growth hormone-releasing factor in man. J. Clin. Endocrinol. Metab. 57: 674, 1983.
Rosenthal S.M., Schriock E.A., Kaplan S.L., Guillemin R., Grumbach M.M. Synthetic human pancreas growth hormone-releasing factor (hpGRF1-44NH2) stimulates growth hormone secretion in normal men. J. Clin. Endocrinol. Metab. 57: 677, 1983.
Thorner M.O., Rivier J., Spiess J., Borges J.L., Vance M.L., Bloom S.L., Rogol A.D., Cronin M.J., Kaiser D.L., Evans W.S., Webster J.D., MacLeod R.M., Vale W. Human pancreatic growth hormone-releasing factor selectively stimulates growth hormone secretion in man. Lancet 1: 24, 1983.
Shibasaki T., Shizume L., Nakahara M., Masuda A., Jibiki K., Demura H., Wakabayashi I., Ling N. Age-related changes in plasma growth hormone response to growth hormone-releasing factor in man. J. Clin. Endocrinol. Metab. 58: 212, 1984.
Wood S.M., Ch’ng J.L.C., Adams F., Webster J.D., Joplin G.F., Mashiter K., Bloom S.R. Abnormalities of growth hormone release in response to human pancreatic growth hormone-releasing factor (GRF1-44) in acromegaly and hypopituitarism. Br. Med. J. 286: 1687, 1983.
Shibasaki T., Shizume K., Masuda A., Nakahara M., Hizuka N., Miyakawa M., Takano K., Demura H., Wakabayashi J., Ling N. Plasma growth hormone response to growth hormone-releasing factor in acromegalic patients. J. Clin. Endocrinol. Metab. 58: 215, 1984.
von Werder K., Müller O.A., Hartl R., Losa M., Stalla K.G. Growth hormone-releasing factor (hpGRF)-stimulation test in normal controls and acromegalic patients. J. Endocrinol. Invest. 7: 185, 1984.
Chiodini P.G., Liuzzi A., Dallabonzana D., Oppizzi G., Verde G.G. Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly. A comparison with thyrotropin-releasing hormone and bromocriptine. J. Clin. Endocrinol. Metab. 60: 48, 1985.
Gelato M.C., Merriam G.R., Vance M.L., Goldman J.A., Webb C., Evans W.S., Rock J., Oldfield E.H., Molitch M.E., Rivier J., Vale W., Reichlin S., Frohman L.A., Loriaux D.L., Thorner M.O. Effects of growth hormone-releasing factor on growth hormone secretion in acromegaly. J. Clin. Endocrinol. Metab. 60: 251, 1985.
Lamberts S.W.J., Verleun T., Oosterom R. The interrelationship between the effects of somatostatin and human pancreatic growth hormone releasing factor on growth hormone release by cultured pituitary tumor cells from patients with acromegaly. J. Clin. Endocrinol. Metab. 58: 250, 1984.
Arosio M., Moriondo P., Travaglini P., Ambrosi B., Beck-Peccoz P., Conti-Puglisi F., Secchi F., Faglia G. Modifications in serum growth hormone concentration induced by sulpiride in acromegalic patients pretreated with dopamine, bromocriptine and metergoline. J. Clin. Endocrinol. Metab. 51: 454, 1980.
Arosio M., Giovanelli M.A., Riva E. Nava C., Ambrosi B., Faglia G. Clinical use of pre -and post- surgical evaluation of abnormal GH responses in acromegaly. J. Neurosurg. 59: 402, 1983.
Brazeau P., Bohlen P., Guillemin R. Mechanism of the antagonism between growth hormone releasing factor (GRF) and somatostatin on the release of pituitary growth hormone. 64th Annual Meeting of the Endocrine Society, San Francisco, CA, (Abstract 538), 1982.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arosio, M., Ambrosi, B., Guglielmino, L. et al. Human pancreatic growth hormone-releasing factor (hpGRF-44) in acromegaly before and after adenomectomy. Modifications induced by somatostatin (GHRIH) infusion. J Endocrinol Invest 8, 449–453 (1985). https://doi.org/10.1007/BF03348536
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348536